VIVEK SUBBIAH to Biomarkers
This is a "connection" page, showing publications VIVEK SUBBIAH has written about Biomarkers.
Connection Strength
0.361
-
Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers. Mol Cancer Ther. 2023 06 01; 22(6):706-716.
Score: 0.101
-
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.
Score: 0.100
-
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448.
Score: 0.064
-
Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study. BMC Med Educ. 2023 Jun 05; 23(1):410.
Score: 0.025
-
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. Eur J Cancer. 2020 09; 136:176-185.
Score: 0.021
-
Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018 07; 59(7):1672-1676.
Score: 0.017
-
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018 08; 36(4):601-607.
Score: 0.017
-
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 10; 15(10):2475-2485.
Score: 0.016